Will Ozempic / semaglutide be FDA-approved for Alzheimer's before 2030?
Plus
30
Ṁ13532030
58%
chance
1D
1W
1M
ALL
Semaglutide (brand names: Ozempic, Rybelsus, and Wegovy) is an antidiabetic and anti-obesity drug. Its developer, Novo Nordisk, has three ongoing phase 3 trials run across the world of semaglutide for Alzheimer’s disease:
NCT04777396: 1,840 participants, started in 2021, results expected in 2026,
NCT05891496: 24 participants, started in 2023, results expected in 2025,
NCT04777409: 1,840 participants, started in 2021, results expected in 2026.
Will semaglutide be approved by the Food and Drug Administration (FDA) for Alzheimer's (or any kind of cognitive impairment) before January 1st, 2030?
Approval can be for the treatment (whether symptomatic or disease-modifying) or prevention of the targeted disease.
This question is managed and resolved by Manifold.
Get
1,000and
3.00
1,0003.00Sort by:
Related questions
Related questions
Will Ozempic be FDA approved for use in type 1 diabetes patients by end of 2024?
11% chance
The FDA will warn about overuse or misuse of semaglutide (Ozempic, Wegovy and Rybelsus) before the end of 2024.
19% chance
Will Kim Jong Un start taking Ozempic (or any GLP-1) by the end of 2025?
36% chance
Will Pfizer announce a weight loss drug competing with Ozempic and Wygovy before 12/31/2024?
35% chance
Will Matt Kaeberlein start taking semaglutide/ozempic by 2030?
41% chance
Will AOH1996 be FDA approved before 2040?
44% chance
Will 10 million Americans be on semaglutide (or yet-to-be-approved equally good or superior alternatives) by the end of 2030?
78% chance
Will a GLP-1 receptor agonist (Ozempic-like drug) be added to public water supplies in the United States by 2075?
30% chance
Will the FDA approve Viagra as a treatment for Alzheimer's before 2030?
19% chance
[ACX 2024] Will the FDA or EMA withdraw approval of semaglutide for the treatment of obesity or diabetes in 2024?
2% chance